Guided Therapeutics Inc
Guided Therapeutics, Inc., a medical technology company, develops medical devices. It focuses on the marketing and sale of LuViva, an advanced cervical scan non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. Th… Read more
Guided Therapeutics Inc (GTHP) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.049x
Based on the latest financial reports, Guided Therapeutics Inc (GTHP) has a cash flow conversion efficiency ratio of 0.049x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-277.00K) by net assets ($-5.65 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Guided Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Guided Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Guided Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Guided Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sin-Kung Logistics Berhad
KLSE:0305
|
0.042x |
|
Ambertech Ltd
AU:AMO
|
0.166x |
|
LCC Infotech Limited
NSE:LCCINFOTEC
|
0.053x |
|
ARIP Public Company Limited
BK:ARIP
|
0.160x |
|
C29 Metals Ltd
AU:C29
|
-0.213x |
|
Nova Organic PCL
BK:NV
|
-0.013x |
|
ROYAL GOLD (RG3.SG)
STU:RG3
|
0.045x |
|
CannBioRx Life Sciences Corp
NASDAQ:ATNFW
|
-0.210x |
Annual Cash Flow Conversion Efficiency for Guided Therapeutics Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Guided Therapeutics Inc from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-4.89 Million | $-1.12 Million | 0.229x | -50.11% |
| 2023-12-31 | $-3.81 Million | $-1.75 Million | 0.459x | -10.58% |
| 2022-12-31 | $-2.88 Million | $-1.48 Million | 0.513x | +75.46% |
| 2021-12-31 | $-5.45 Million | $-1.59 Million | 0.292x | +69.27% |
| 2020-12-31 | $-10.86 Million | $-1.88 Million | 0.173x | +262.93% |
| 2019-12-31 | $-16.93 Million | $-806.00K | 0.048x | -44.83% |
| 2018-12-31 | $-15.82 Million | $-1.36 Million | 0.086x | +46.30% |
| 2017-12-31 | $-19.40 Million | $-1.14 Million | 0.059x | -- |